New hope for hard-to-treat lymphoma: experimental drug enters phase 2 trial
NCT ID NCT07180771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BR101801 in 44 people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug alone, without other cancer treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NODAL TFH CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a Five-Drug combo tame a tough lymphoma without standard chemo?
- Can a targeted pill boost Chemotherapy's punch against a rare lymphoma?
- A microchip implanted in tumors could reveal which drugs work best
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Experimental drug combo aims to tackle tough lymphoma